April 29 (Reuters) - The chief executive of the world's
largest vaccine maker, GlaxoSmithKline, said the global
push to develop an immunisation against the coronavirus would
not lead to widely available products before the second half of
next year.
"If things go right ... to get to scale of manufacturing in
the hundreds of millions (of doses) is going to be in the second
half of next year," CEO Emma Walmsley told a media briefing
after the release of first-quarter results.
(Reporting by Ludwig Burger; Editing by Edmund Blair)